Tumor necrosis factor blockers and reactivation of latent tuberculosis.
Joseph
J
Keane
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000276:immunology; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor; D014376:Tuberculosis / Q000139:chemically induced* / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept